ReviewFrontiers in immunology2017
Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications.
Review in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04324996 (A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19), which is not on this map. Cited by 98 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19
Who cites it
98 citing papers in PubMed, 162 citations in OpenAlex.
- Engineering CLL-1 CAR-NK cells via mRNA-LNP for potent antitumor activity and reversal of HLA-E-mediated resistance in acute myeloid leukemia.Journal of experimental & clinical cancer research : CR · 2026Article
- Feeder-free ex vivo expansion of cord blood-derived natural killer cells for enhanced proliferation and functional maturation.Scientific reports · 2026Article
- Optimal genetic feeder cell-expanded and engineered NK cell products are composed of CD56Cancer immunology, immunotherapy : CII · 2026Article
- Umbilical cord blood infusion enhances hematopoietic recovery and improves survival in elderly AML patients with chemotherapy-induced myelosuppression: a retrospective study.Frontiers in oncology · 2026Article
- CAR-NK cell therapy in multiple myeloma: from preclinical and clinical landscape to joining the force for treatment strategies optimization.Cell communication and signaling : CCS · 2025Review
- Umbilical cord blood infusion in the treatment of aplastic anemia: A single center prospective study.Scientific reports · 2025Article
- Reduced Cish expression by siRNA knockdown in Natural Killer cells promotes anti-tumor effects against gastric cancer cell lines.Discover oncology · 2025Article
- Beyond CAR-T Cells: exploring CAR-NK, CAR-M, and CAR-γδ T strategies in solid tumor immunotherapy.Frontiers in immunology · 2025Review
- Aclacinomycin enhances the killing effect of allogeneic NK cells on acute myeloid leukemia cells by inducing immunogenic cell death.Frontiers in immunology · 2025Article
- Application and prospects of genetic engineering in CAR-NK cell therapy.Frontiers in immunology · 2025Review
- Engineered iPSC-derived natural killer cells: recent innovations in translational innate anti-cancer immunotherapy.Clinical & translational immunology · 2025Review
- Advances in chimeric antigen receptor-natural killer cell therapy: from mechanisms and preclinical studies to clinical application.Frontiers in oncology · 2025Review
- CAR-NK cell for gynecological cancers: immune microenvironment remodeling and immunotherapeutic strategies.Frontiers in immunology · 2025Review
- Immunotherapy of chimeric antigen receptor NK cells: status and its promising future.Frontiers in immunology · 2025Review
- The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.Experimental hematology & oncology · 2024Review
- CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside.Molecular cancer · 2024Review
- Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy.Journal of translational medicine · 2024Review
- Evolution of natural killer cell-targeted therapy for acute myeloid leukemia.International journal of hematology · 2024Review
- Granulocyte Colony Stimulating Factor-Mobilized Peripheral Blood Mononuclear Cells: An Alternative Cellular Source for Chimeric Antigen Receptor Therapy.International journal of molecular sciences · 2024Review
- Genetic Manipulation Approaches to Enhance the Clinical Application of NK Cell-Based Immunotherapy.Stem cells translational medicine · 2024Review
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells are lymphocytes of the innate immune system able to kill different targets such as cancer cells and virally infected cells without prior activation making then attractive candidates for cancer immunotherapy. Umbilical cord blood (UCB) has become a source of hematopoietic stem cells for transplantation but as we gain a better understanding of the characteristics of each immune cell that UCB contains, we will also be able to develop new cell therapies for cancer. In this review, we present what is currently known of the phenotype and functions of UCB NK cells and how these cells could be used in the future for cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.